Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-01-26

FDA Approved: XCOPRI — Supplemental Application (SK Life Science, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for XCOPRI (cenobamate) from SK Life Science, Inc., resulting in an updated labeling for the drug.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Xcopri (cenobamate)

Snippet

SUPPL AP for XCOPRI (CENOBAMATE)